Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Slim Pickens who wrote (3536)	12/12/1997 7:05:00 PM
From: blankmind	Respond to of 23519

-- Needle vs. Muse: From the 10k: Here's what Vivus's competition uses: "Needle Injection Therapy. This form of treatment involves the needle injection of pharmacologic agents directly into the penis. These agents are generally vasoactive compounds such as alprostadil alone or in combination with phentolamine and papaverine. This form of treatment requires a prescription from a physician and -3- <PAGE> 5 instruction on self-injection. Side effects may include pain associated with injection, local pain and aching, priapism (persistent prolonged erections), fibrosis (build-up of scar tissue) and bleeding. " -- And here's how Vivus's Muse is delivered: "Ease of Administration. The Company's transurethral system for erection is easy to use with minimal instruction, unlike needle injection therapy that requires precise injection into a corpus cavernosum. -4- <PAGE> 6 Non-invasive. The Company's transurethral system for erection utilizes urethral delivery, permitting topical application to the urethral lining." -== Okay. Knowing this. I feel much better about my investment. Granted, Muse isn't like taking a vitamin. But it's not like taking a needle either. Out.